Athenex (NASDAQ:ATNX) has been given a $20.00 target price by research analysts at Deutsche Bank in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the stock. Deutsche Bank’s price objective would indicate a potential upside of 16.21% from the stock’s current price.
A number of other equities analysts also recently commented on the company. BidaskClub downgraded Athenex from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th. JPMorgan Chase & Co. began coverage on Athenex in a research report on Wednesday, October 18th. They set a “neutral” rating and a $22.20 price objective for the company. Finally, Laidlaw began coverage on Athenex in a research report on Tuesday, September 19th. They set a “buy” rating and a $36.00 price objective for the company. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Athenex currently has an average rating of “Buy” and an average target price of $27.64.
Athenex (NASDAQ:ATNX) traded up $0.51 during midday trading on Wednesday, reaching $17.21. The company’s stock had a trading volume of 453,900 shares, compared to its average volume of 196,625. The firm has a market cap of $1,010.00 and a P/E ratio of -6.24. Athenex has a 52 week low of $11.21 and a 52 week high of $20.79.
Athenex (NASDAQ:ATNX) last released its earnings results on Thursday, November 9th. The company reported ($0.30) earnings per share for the quarter. equities analysts forecast that Athenex will post -2.75 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System acquired a new position in Athenex in the third quarter valued at approximately $198,000. Bank of New York Mellon Corp purchased a new stake in Athenex in the second quarter valued at approximately $240,000. Tudor Investment Corp ET AL purchased a new stake in Athenex in the second quarter valued at approximately $320,000. Schwab Charles Investment Management Inc. purchased a new stake in Athenex in the third quarter valued at approximately $524,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Athenex in the second quarter valued at approximately $601,000. 2.93% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/19/athenex-atnx-pt-set-at-20-00-by-deutsche-bank.html.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.